Galectin-1 inhibits oral-intestinal allergy syndrome

Rui-Di Xie; Ling-Zhi Xu; Li-Tao Yang; Shuai Wang; Qi Liu; Zhi-Gang Liu; Ping-Chang Yang

doi:10.18632/oncotarget.14571

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Galectin-1 inhibits oral-intestinal allergy syndrome

Rui-Di Xie, Ling-Zhi Xu, Li-Tao Yang, Shuai Wang, Qi Liu, Zhi-Gang Liu and Ping-Chang Yang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:13214-13222. https://doi.org/10.18632/oncotarget.14571

Metrics: PDF 2246 views | HTML 2500 views | ?

Abstract

Rui-Di Xie1,2,*, Ling-Zhi Xu1,*, Li-Tao Yang3,4,*, Shuai Wang3, Qi Liu2, Zhi-Gang Liu1, Ping-Chang Yang1

1The Research Center of Allergy & Immunology, Shenzhen University School of Medicine, Shenzhen, China

2Periodontal Department, the Affiliated Hospital of Zunyi Medical College, Zunyi, China

3The ENT Hospital of Shenzhen University and Shenzhen ENT Institute, Shenzhen, China

4Brain Body Institute, McMaster University, Hamilton, ON, Canada

*These authors contributed equally to this work

Correspondence to:

Ping-Chang Yang, email: [email protected]

Zhi-Gang Liu, email: [email protected]

Qi Liu, email: [email protected]

Keywords: oral mucosa, oral allergy, peanut, micro RNA-98, galectin-1

Received: August 25, 2016 Accepted: December 27, 2016 Published: January 10, 2017

ABSTRACT

Background and aims: The pathogenesis of oral-intestinal allergy syndrome (OIAS) has not been well understood. Published data indicate that galectin (Gal) 1 has immune regulatory functions. This study tests a hypothesis that Gal1 inhibits oral-intestinal allergy syndrome.

Methods: Mice were sensitized to peanut extracts (PE) via the buccal mucosa with or without using Gal1 together.

Results: Upon re-exposure to specific antigen, the OIAS mice showed the systemic allergic response, the oral allergic reactions, and intestinal allergic inflammation, including increases in serum histamine, drop of the core temperature, higher levels of PE-specific IgE and interleukin (IL)-4. Increases in mast cell and eosinophil in the oral mucosa and intestinal mucosa were also observed. The OIAS was inhibited by co-administration with Gal1 via a mechanism of suppressing micro RNA (miR)-98 and reversing the expression of IL-10 in CD14+ cells in the intestine.

Conclusions: The OIAS can be induced by applying specific antigens to the oral mucosa, which can be inhibited by co-administration with Gal1.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14571

Publication Alerts

Research Papers:

Galectin-1 inhibits oral-intestinal allergy syndrome

Abstract